Therapeutic-area Dossier
Respiratory
Therapeutic-area Dossier for Respiratory (respiratory medicines). Australian brands, active ingredients, PBS-listed treatments, PBAC outcomes — compiled…
- Brand: AIROMIR
- Brand: ALVESCO
- Brand: ARNUITY ELLIPTA
- Brand: BRICANYL
- Brand: BRONCHITOL
- Brand: CIPLA
- Sponsor: Cipla
- Sponsor: Arrotex Pharmaceuticals
- Sponsor: GlaxoSmithKline
- Sponsor: Neo Health (OTC)
What is
Respiratory The Respiratory therapeutic area encompasses treatments and management strategies for respiratory conditions, with 262 brands currently registered in Australia.
Brands registered in Respiratory The top registered brands in this area are:
— AIROMIR — ALVESCO — ARNUITY ELLIPTA — BRICANYL — BRONCHITOL — CIPLA — CLARATYNE — CORTATE — DUPIXENT — FASENRA — FLIXOTIDE — FORADILE
Sponsor landscape
The respiratory area has 85 active sponsors. The top sponsors include Cipla, Arrotex Pharmaceuticals, GlaxoSmithKline, Neo Health (OTC), AstraZeneca, Noumed Pharmaceuticals, Novartis Pharmaceuticals, and Boehringer Ingelheim.
PBS and regulatory activity
Twenty-eight brands in the respiratory area have PBS-listed items, with the latest PBS schedule dated 1 May 2026. The most recent PBAC outcome in this area is from 1 December 2025, with 47 brands holding PBAC outcomes on record. The latest AusPAR is dated 20 March 2024, with 21 brands holding AusPARs on record.